PODD INVESTOR DEADLINE: Insulet Corporation Investors with Substantial Losses Have Opportunity to Lead the Insulet Class Action Lawsuit Before August 31, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Insulet Corporation for alleged violations of the Securities Exchange Act of 1934. Investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, and suffered substantial losses, have until August 31, 2026, to seek appointment as lead plaintiff. The lawsuit alleges Insulet made false or misleading statements regarding defective manufacturing controls that led to multiple Medical Device Corrections for its Omnipod products.
Insulet Corp (PODD) Shares Fall 3.0% -- What GF Score of 81 Tells Investors
Insulet Corp (PODD) shares fell 3.0% to $146.87, but the company's GF Score of 81/100 indicates strong overall performance, with a high Growth rank despite a low Valuation rank. The stock appears significantly undervalued according to GF Value, suggesting a potential opportunity for investors. Insider activity also shows net buying, reflecting confidence in the company's future.
Lost Money on Insulet Corporation (PODD)? A Class Action Suit is Seeking Recovery - Contact SueWallSt
SueWallSt is encouraging investors who purchased Insulet Corporation (PODD) securities between February 21, 2025, and May 26, 2026, to assess their potential losses, as shares declined significantly following two Medical Device Corrections. The class action lawsuit alleges that Insulet made false and misleading statements about the safety and manufacturing quality of its Omnipod insulin delivery systems, leading to substantial stock drops. Investors have until August 31, 2026, to apply for lead plaintiff, though participation is possible without this action.
Lost Money on Insulet Corporation (PODD)? A Class Action Suit is Seeking Recovery - Contact SueWallSt
SueWallSt is encouraging investors who purchased Insulet Corporation (PODD) securities between February 21, 2025, and May 26, 2026, to assess potential losses due to alleged misleading statements regarding product safety and manufacturing quality. The class action suit follows two Medical Device Corrections for Omnipod insulin delivery systems, which caused Insulet shares to decline by over $90 per share. Investors have until August 31, 2026, to apply for lead plaintiff status.
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Insulet Corporation (NASDAQ: PODD) and some of its officers for alleged violations of federal securities laws. The lawsuit claims that Insulet made false and misleading statements about its manufacturing controls and procedures, creating a risk of product safety violations. Investors who purchased Insulet securities between May 21, 2025, and May 26, 2026, are encouraged to join the case, with a lead plaintiff deadline of August 31, 2026.
INSULET CORPORATION (PODD) SHAREHOLDER ALERT Bernstein
Bernstein Liebhard LLP reminds Insulet Corporation (NASDAQ: PODD) investors of an upcoming August 31, 2026 deadline for a securities fraud class action lawsuit. The lawsuit alleges that Insulet made materially false and misleading statements about its business operations, growth prospects, and financial stability between February 21, 2025 and May 26, 2026, causing investors significant losses. Affected investors are encouraged to join the class action or contact Investor Relations Manager Peter Allocco.
14,672 Shares in Insulet Corporation $PODD Purchased by Aurora Investment Counsel
Aurora Investment Counsel has acquired a new stake of 14,672 shares in Insulet Corporation (NASDAQ:PODD), valued at approximately $2.234 million, during the second quarter. This move is part of broader institutional interest, with other major investors also adjusting their positions in the medical instruments supplier. Despite legal concerns regarding a federal securities class action and allegations of undisclosed manufacturing defects, Insulet reported strong Q1 earnings, surpassing analyst expectations for both EPS and revenue, and analysts project continued growth for the company.
BioNTech SE Stock Pops As Traders Refocus On Oncology
BioNTech SE (BNTX) stock surged by 23.44% despite lower COVID-19 revenues and wider losses in Q2 2026, as traders are now focusing on the company's strong oncology pipeline. BioNTech boasts a substantial cash pile of €16.6 billion, active share buybacks, and 14 pivotal oncology trials, positioning it for future growth. The European Commission's approval of an updated COVID vaccine and a planned CEO transition by 2027 further support the shift towards a diversified biopharma strategy.
Deadline Alert: Insulet Corporation (PODD) Shareholders Who
Glancy Prongay Wolke & Rotter LLP is urging Insulet Corporation (PODD) shareholders who lost money to contact them regarding a securities fraud lawsuit. The lawsuit alleges that Insulet made materially false and/or misleading statements between February 21, 2025, and May 26, 2026, concerning defective manufacturing controls that led to product recalls and a drop in stock price. Investors have until August 31, 2026, to file a lead plaintiff motion.
Deadline Alert: Insulet Corporation (PODD) Shareholders Who
Glancy Prongay Wolke & Rotter LLP is urging Insulet Corporation (PODD) shareholders who lost money to contact them regarding a securities fraud lawsuit. The lawsuit alleges that Insulet made misleading statements and failed to disclose manufacturing defects that led to medical device corrections and subsequent drops in stock price. Investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, have until August 31, 2026, to file a lead plaintiff motion.
INSULET DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL,
The Rosen Law Firm reminds Insulet Corporation (NASDAQ: PODD) investors with losses over $100,000 to secure counsel before the August 31, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Insulet made false or misleading statements regarding defective manufacturing controls that created a risk of violating safety regulations or causing injury. Investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, may be entitled to compensation.
Insulet Corporation Stockholders May Be Eligible to Lead the Class Action Against PODD; Contact Robbins LLP Before the August 31, 2026 Deadline for Information
Robbins LLP reminds investors that a securities class action has been filed against Insulet Corporation (NASDAQ: PODD) for allegedly making false or misleading statements regarding its manufacturing controls and product safety between February 21, 2025, and May 26, 2026. The lawsuit claims Insulet failed to disclose manufacturing deficiencies that led to two Medical Device Corrections for its Omnipod products, causing stock price drops. Investors who suffered losses during this period are encouraged to contact Robbins LLP by the August 31, 2026 deadline to potentially serve as lead plaintiff.
TEM Stock Dips As Tempus AI Bets $1.5B On Personalis
Tempus AI (TEM) stock dipped after announcing a $1.5 billion all-stock acquisition of Personalis (PSNL), a move intended to integrate Personalis's tumor-informed MRD tests into Tempus AI's precision oncology platform. Despite the acquisition causing an initial drop in TEM shares due to concerns over valuation and dilution, Tempus AI simultaneously reported strong Q2 revenues, raised full-year guidance, and achieved profitability. The deal is strategically important for Tempus AI's expansion into the $20 billion MRD market, though it faces scrutiny regarding potential conflicts of interest.
Portnoy Law Firm Announces Class Action on Behalf of Insulet Corporation Investors
The Portnoy Law Firm has announced a class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made misleading statements regarding defective manufacturing controls, which led to two voluntary Medical Device Corrections for its Omnipod products, causing significant drops in stock price. Investors have until August 31, 2026, to file a lead plaintiff motion and are encouraged to contact the firm for a complimentary case evaluation.
Portnoy Law Firm Announces Class Action on Behalf of Insulet Corporation Investors
The Portnoy Law Firm has announced a class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made false or misleading statements regarding defective manufacturing controls and undisclosed risks, leading to two Medical Device Corrections for its Omnipod products. Investors are encouraged to contact the firm to discuss their legal rights, with a lead plaintiff motion deadline of August 31, 2026.
PODD Deadline Alert: Levi & Korsinsky Reminds Insulet Corporation (PODD) Investors of Securities Class Action Deadline on August 31, 2026
Levi & Korsinsky, LLP is reminding investors of Insulet Corporation (NASDAQ: PODD) about the August 31, 2026, deadline to serve as lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Insulet made misleading statements regarding its manufacturing quality, leading to significant stock price declines after two voluntary Medical Device Corrections for its Omnipod insulin delivery systems. Investors who purchased PODD securities between February 21, 2025, and May 26, 2026, and suffered losses are encouraged to seek a free case evaluation.
AIXC Stock Whipsaws Higher As Traders Hunt Volatility
AIxCrypto Holdings Inc. (AIXC) stock has experienced extreme volatility, dropping 12.58% due to negative sentiment from regulatory crackdown headlines, despite a recent intraday spike from under $1 to $3.14. While the company's financials show deep losses and negative returns, it maintains working capital and minimal debt, allowing it some breathing room. Traders are drawn to AIXC for its significant price swings and liquidity, treating it as a short-term momentum play rather than a long-term investment.
Portnoy Law Firm Announces Class Action on Behalf of Insulet Corporation Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of Insulet Corporation (NASDAQ: PODD) investors who purchased securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made false or misleading statements regarding defective manufacturing controls, which led to two medical device corrections for its Omnipod products and subsequent drops in stock price. Investors have until August 31, 2026, to file a lead plaintiff motion.
PODD Deadline Alert: Levi & Korsinsky Reminds Insulet Corporation (PODD) Investors of Securities Class Action Deadline on August 31, 2026
Levi & Korsinsky, LLP is reminding Insulet Corporation (PODD) investors of the August 31, 2026, deadline to seek lead plaintiff status in a securities class action lawsuit. The lawsuit alleges that Insulet made misleading statements regarding its manufacturing quality, leading to significant stock price declines after two voluntary Medical Device Corrections for its Omnipod insulin delivery systems. Investors who purchased PODD securities between February 21, 2025, and May 26, 2026, and suffered losses are encouraged to contact the firm for a free case evaluation.
Rothschild Redburn initiates ResMed stock coverage with neutral rating
Rothschild Redburn has initiated coverage on ResMed Inc. (NYSE:RMD) with a Neutral rating and a price target of $230.00. The firm acknowledges ResMed's market leadership in obstructive sleep apnoea treatment but notes structural barriers and struggles to find meaningful upside to consensus estimates, viewing the current valuation as full. Despite recent strong fiscal fourth-quarter results, analysts are factoring in challenges such as the impact of GLP-1 pharmaceuticals and wearable health devices.
PODD Shareholders Have Opportunity to Lead Insulet Corporation Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Insulet Corporation (NASDAQ:PODD) and its officers. The lawsuit alleges that Insulet made materially false and misleading statements regarding defective manufacturing controls, which created a heightened risk of safety violations. Insulet shareholders who purchased securities between May 21, 2025, and May 26, 2026, are encouraged to join the case, with a lead plaintiff deadline of August 31, 2026.
CDE Stock Slips As Coeur Mining Misses Q2 Targets
Coeur Mining (CDE) stock has fallen by 3.99% after missing its Q2 adjusted EPS and revenue targets, with EPS at $0.12 against an expected $0.26, and revenue at $1.09B versus $1.24B. Despite the misses, the company maintains strong margins and positive cash flow, presenting a complex scenario for traders weighing short-term price reactions against underlying business health. The article highlights the importance of risk management and rule-based trading in navigating the stock's increased volatility.
Insulet (PODD) Stock Slumps As Earnings Beat Collides With Guidance Reset
Insulet (PODD) beat Q2 expectations for EPS and revenue, and raised its 2026 adjusted EPS growth outlook to at least 30%. However, the stock slumped over 20% due to trimmed 2026 Drug Delivery/Omnipod growth guidance and higher churn among type 2 diabetes users. Analysts have slashed price targets but largely maintain bullish ratings, creating a high-volatility situation for traders.
Insulet Corp. stock outperforms competitors on strong trading day
Insulet Corp. (PODD) saw its stock increase by 5.96% to $148.03, outperforming the broader market on a generally negative trading day. This rise broke a two-day losing streak for the company, while the S&P 500 and Dow Jones Industrial Average experienced declines.
Bragar Eagel & Squire, P.C. Urges Insulet Corporation Investors to Contact the Firm Before August 31st Lead Plaintiff Deadline
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Insulet Corporation (NASDAQ:PODD) on behalf of investors who purchased securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made materially false and misleading statements regarding defective manufacturing controls that posed a risk of injury and violation of safety regulations. Investors have until August 31, 2026, to apply to be appointed as lead plaintiff.
HL Stock Slips As Hecla Mining Misses Q2 Revenue
Hecla Mining Company (HL) stock slipped by 4.22% after missing Q2 revenue expectations, reporting $333.9M against a $368.8M consensus. Despite the shortfall, the company exhibits strong underlying fundamentals, including a robust balance sheet with no long-term debt and solid profit margins. Traders are now evaluating whether the stock's recent rally was overextended, leading to cautious sentiment though no panic sell-off.
At 55 With No Dividend Income, $1,500 a Month Into the SCHD ETF Is the Last Lever You Have
For a 55-year-old with no dividend income and a decade until retirement, contributing $1,500 monthly to the SCHD ETF can be a strategy for share accumulation, though dividend compounding will not be the primary driver due to the short timeframe. The article highlights that SCHD's dividend growth has slowed recently, leading to a real income cut when considering inflation. It recommends splitting contributions between SCHD and a broad market index fund to gain diversified exposure beyond SCHD's sector concentration.
Maude Monthly: Insulet Omnipod Lots Outside of Recall Appear to Be Showing Same Defects; Medline Reports Thousands of Backlogged Reports; ConvaTec Subsidiary Discloses Hundreds of Deaths but Little Investigation of Their Causes
A Capitol Forum analysis of the FDA's MAUDE database reveals that adverse event reports for Insulet Corporation's Omnipod 5 insulin pump, describing defects similar to those in two earlier recalls, hit a monthly high in July. The article also mentions thousands of backlogged reports from Medline and hundreds of deaths disclosed by a ConvaTec subsidiary with minimal investigation into their causes. The full article content is behind a subscriber paywall.
PODD Shareholder Alert: August 31, 2026 Lead Plaintiff Deadline in Insulet Corporation Securities Class Action - Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for Insulet Corporation (NASDAQ: PODD), notifying investors of a securities class action lawsuit. The lawsuit alleges that Insulet made materially false and misleading statements regarding defective manufacturing controls between February 21, 2025, and May 26, 2026. Shareholders who purchased shares during this period are encouraged to contact The Gross Law Firm by the lead plaintiff deadline of August 31, 2026.
SXTC Stock Rockets On Momentum As Balance Sheet Shines
China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) has experienced a significant stock surge, rising by 27.47% due to positive market sentiment and strong buying interest. The company's balance sheet reveals approximately $28 million in cash and minimal debt, providing a substantial liquidity cushion. Despite low revenue, its price-to-book ratio around 0.07 suggests the market heavily discounts its stated book value, making it an attractive, albeit volatile, option for momentum traders.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Insulet Corporation (PODD)
Bernstein Liebhard LLP has announced a securities fraud class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased shares between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made materially false and misleading statements about its business, growth, and financial stability, leading to artificially inflated stock prices and investor losses. Shareholders are encouraged to join the lawsuit, with a deadline to file as lead plaintiff by August 31, 2026.
Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY): Bloom Energy Corporation (NYSE: BE); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf
The Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Bloom Energy, GPGI (f/k/a CompoSecure), and Insulet Corporation. The investigations follow allegations of misleading statements and undisclosed issues that led to stock declines for these companies. Shareholders who held shares before specific dates are encouraged to contact the firm for potential shareholder governance actions.
AUGUST 31, 2026 INVESTOR DEADLINE: Insulet Corporation (PODD) Investors with Substantial Losses Have Opportunity to Lead the Insulet Class Action Lawsuit Before August 31, 2026 Deadline - RGRD Law
Robbins Geller Rudman & Dowd LLP announced an investor deadline of August 31, 2026, for a class action lawsuit against Insulet Corporation (NASDAQ: PODD). Investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, and suffered substantial losses, can seek to be appointed as lead plaintiff. The lawsuit alleges that Insulet made false or misleading statements regarding defective manufacturing controls that led to product recalls and a drop in stock price.
AUGUST 31, 2026 INVESTOR DEADLINE: Insulet Corporation
Robbins Geller Rudman & Dowd LLP announces an investor deadline of August 31, 2026, for individuals who purchased Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025, and May 26, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that Insulet made false and misleading statements regarding defective manufacturing controls that led to product safety violations and recalls. Investors who suffered substantial losses are encouraged to contact the law firm to learn more about leading the class action.
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Futu Holdings Limited (FUTU), and Hub Group, Inc. (HUBG), and Insulet Corporation (PODD) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC has announced lead plaintiff deadlines for shareholder class action lawsuits against Futu Holdings Limited (FUTU), Hub Group, Inc. (HUBG), and Insulet Corporation (PODD). Investors who suffered losses on shares of these companies during specified periods are encouraged to contact the firm to discuss their legal rights. The deadlines to seek appointment as lead plaintiff are August 25, 2026 for Futu, August 28, 2026 for Hub Group, and August 31, 2026 for Insulet.
2 WEEK INVESTOR DEADLINE: Insulet Corporation Investors with Substantial Losses Have Opportunity to Lead the Insulet Class Action Lawsuit Before August 31, 2026 Deadline - PODD
Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Insulet Corporation (NASDAQ: PODD) for alleged violations of the Securities Exchange Act of 1934. Investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, and suffered substantial losses, have until August 31, 2026, to seek appointment as lead plaintiff. The lawsuit alleges that Insulet made false or misleading statements regarding defective manufacturing controls and undisclosed risks of injury or safety regulation violations, which led to a significant drop in stock price following two Medical Device Corrections.
Insulet Corp. stock underperforms Monday when compared to competitors
Insulet Corp. stock (PODD) declined by 2.54% to $139.70 on Monday, underperforming the broader market. This drop occurred on a day when both the S&P 500 Index and the Dow Jones Industrial Average also saw declines. This marks the second consecutive day of losses for the company's stock.
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Insulet Corporation (NASDAQ: PODD) and its officers, alleging violations of federal securities laws. The lawsuit claims that Insulet made false and misleading statements about defective manufacturing controls and procedures, creating a heightened risk of safety violations or injury. Investors who purchased Insulet securities between May 21, 2025, and May 26, 2026, are encouraged to join the case, with a lead plaintiff deadline of August 31, 2026.
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP is reminding investors of a class action lawsuit against Insulet Corporation (NASDAQ: PODD) for alleged securities fraud. The lawsuit claims Insulet made false statements regarding defective manufacturing controls and safety violations, which impacted a greater number of its Pod Products than disclosed. Investors who purchased shares between February 21, 2025, and May 26, 2026, and suffered losses are encouraged to contact the firm before the August 31, 2026 deadline to potentially serve as lead plaintiff.
OneDigital Investment Advisors LLC Buys Shares of 44,275 Insulet Corporation $PODD
OneDigital Investment Advisors LLC has acquired 44,275 shares of Insulet Corporation (NASDAQ:PODD) for approximately $6.7 million, representing 0.06% of the company. Despite strong quarterly results from Insulet, including a 23.5% revenue increase and beating EPS expectations, the stock faces an overhang from pending securities litigation regarding manufacturing and product reliability. Analysts currently maintain a consensus "Hold" rating for the medical instruments supplier.
PODD Shareholder Alert: Insulet Corporation Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
Levi & Korsinsky, LLP has issued a shareholder alert for Insulet Corporation (NASDAQ: PODD) investors regarding a pending securities class action lawsuit. The lawsuit names six senior executives as individual defendants, alleging misleading statements about manufacturing quality and safety that led to significant share declines after two Medical Device Corrections. Investors who purchased Insulet shares between February 21, 2025, and May 26, 2026, are encouraged to contact Levi & Korsinsky to recover losses, with a lead plaintiff deadline of August 31, 2026.
PODD Shareholder Alert: Insulet Corporation Securities
Levi & Korsinsky, LLP has alerted investors in Insulet Corporation (NASDAQ: PODD) about a pending securities class action lawsuit. The lawsuit names senior executives as individual defendants for alleged cumulative losses stemming from defective Omnipod manufacturing controls. Investors who purchased shares between February 21, 2025, and May 26, 2026, may qualify to recover losses, with a lead plaintiff deadline set for August 31, 2026.
GSA Capital Partners LLP Acquires New Holdings in Insulet Corporation $PODD
GSA Capital Partners LLP has acquired a new stake of 11,310 shares in Insulet Corporation (NASDAQ:PODD) during the second quarter, valued at approximately $1.72 million. Other institutional investors have also adjusted their holdings, while analysts have issued various ratings and price targets, with a consensus "Hold" rating and a target price of $195.40. The company reported strong Q1 earnings, but faces a federal securities class action lawsuit concerning alleged manufacturing defects.
PODD UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026
Faruqi & Faruqi, LLP is reminding Insulet (NASDAQ: PODD) investors of the August 31, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Insulet made false and misleading statements regarding defective manufacturing controls, which led to multiple product recalls of Omnipod devices and subsequent drops in stock price. Investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, are encouraged to contact the firm to discuss their legal options.
PODD FINAL DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Insulet Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important August 31 Deadline in Securities Class Action – PODD
The Rosen Law Firm is reminding investors of Insulet Corporation (NASDAQ: PODD) who suffered losses exceeding $100K to secure counsel before the August 31, 2026, lead plaintiff deadline in a securities class action. The lawsuit alleges that Insulet's manufacturing controls were defective, leading to a foreseeable risk of violating safety regulations and causing injury, which resulted in investor damages. The firm encourages affected investors to contact them to join the class action.
Does Stronger Q2 Results And Higher Guidance Change The Bull Case For Insulet (PODD)?
Insulet Corporation reported strong Q2 2026 results with significant revenue and net income growth, along with updated double-digit GAAP revenue growth guidance for the third quarter and full year. This positive financial outlook reinforces the company's growth narrative for its Omnipod platform, despite ongoing Class I pod recalls which pose regulatory and product quality risks. The article suggests that while growth is strong, investors should consider the implications of these recalls on the company's long-term outlook.
PODD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Insulet Corporation Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Insulet Corporation (NASDAQ: PODD) and its officers for alleged violations of federal securities laws. The lawsuit claims Insulet made materially false and misleading statements regarding its business and compliance, specifically concerning defective manufacturing controls and heightened risk of product safety issues. Investors who purchased Insulet securities between May 21, 2025, and May 26, 2026, have until August 31, 2026, to request to be appointed lead plaintiff.
Insulet Corp. stock outperforms competitors despite losses on the day
Insulet Corp. (PODD) stock fell by 2.12% to $143.34 on Friday, breaking a six-day winning streak, despite a broader market decline with the S&P 500 and Dow Jones also experiencing losses. The company's stock still managed to outperform its competitors, even with the daily drop. This movement occurred during a generally rough trading session for the stock market.
Deadline Alert: Insulet Corporation (PODD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is reminding investors of a class action lawsuit against Insulet Corporation (PODD) with an August 31, 2026 deadline for lead plaintiff motions. The lawsuit alleges that Insulet made misleading statements and failed to disclose defective manufacturing controls, which led to a significant drop in stock price following product recalls related to insulin under-delivery. Investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, and suffered losses are encouraged to contact the firm.
Deadline Alert: Insulet Corporation (PODD) Shareholders Who
Glancy Prongay Wolke & Rotter LLP is urging Insulet Corporation (NASDAQ: PODD) shareholders who lost money to contact them regarding a securities fraud lawsuit. The class action alleges Insulet made misleading statements and failed to disclose defective manufacturing controls, leading to product recalls and a significant drop in stock price. Investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, have until August 31, 2026, to file a lead plaintiff motion.
